

1 **The real-world effectiveness of an intranasal spray A8G6**
2 **antibody cocktail in the post-exposure prophylaxis of**
3 **COVID-19**

4
5 Xiaosong Li^{1*}, Pai Peng^{2,3*}, Haijun Deng^{2,3*}, Qian Yang¹, Shi Chen¹, Benhua
6 Li¹, Miao He⁴, Zhu Yang⁵, Ni Tang^{2,3#}, Ailong Huang^{2,3#}

7
8 **Author Affiliations:**

9 ¹Clinical Molecular Medicine Testing Center, The First Affiliated Hospital of
10 Chongqing Medical University, Chongqing 400016, China.

11 ²Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of
12 Education), Department of Infectious Diseases, Chongqing Medical University,
13 Chongqing, China.

14 ³Institute for Viral Hepatitis, the Second Affiliated Hospital of Chongqing
15 Medical University, Chongqing, China.

16 ⁴Laboratory Animal Center of Chongqing Medical University, Chongqing,
17 China

18 ⁵Department of Gynecology and Obstetrics, the Second Affiliated Hospital of
19 Chongqing Medical University

20

21 * These authors contributed equally to this work.

22 # **Correspondence:** Ai-long Huang (ahuang@cqmu.edu.cn) and Ni Tang
23 (nitang@cqmu.edu.cn)

24

25 Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of
26 Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the
27 Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

28 Yixue Yuan Road No.1, Chongqing, 400016, P. R. China.

29 Tel/Fax: 86-23-68486780

30 **Summary**

31 **Background** Due to the continuous appearance of novel SARS-CoV-2
32 variants that are resistant to approved antibodies and leading to the epidemic
33 rebound, several approved neutralizing antibodies have been paused for their
34 usage against COVID-19. Previously, we identified A8G6, an antibody
35 combination of two synergic SARS-CoV-2 neutralizing antibodies 55A8 and
36 58G6, that showed broad neutralizing activities against Omicron variants.
37 When administrated by the nasal spray delivery system, A8G6 showed
38 promising efficacy in COVID-19 animal models and also showed favorable
39 safety profile in preclinical models as well as in a first-in-human trial. The aim
40 of this study is to evaluate the real-world efficacy of A8G6 neutralizing antibody
41 nasal spray in post-exposure prevention of COVID-19.

42

43 **Methods** From November 27, 2022 to January 31, 2023, an open-label,
44 non-randomized, two-arm, blank-controlled, investigator-initiated trial was
45 conducted in Chongqing, China. High-risk healthy participants (18-65 years)
46 within 72 hours after close contact to SARS-CoV-2 infected individuals were
47 recruited and received a three-dose (1.4 mg/dose) A8G6 nasal spray
48 treatment daily or no treatment (blank control) for 7 consecutive days. The
49 primary end points were 1) the occurrence of positive SARS-CoV-2 RT-PCR
50 cases in A8G6 treated group vs blank control group at the end of day 7; 2) time
51 to SARS-CoV-2 positive conversion at the end of day 7. The secondary end

52 points were 1) viral load of SARS-CoV-2 when participants became
53 SARS-CoV-2 positive; 2) the time from SARS-CoV-2 infection to negative
54 COVID-19 conversion. Safety end point of the nasal spray AG86 was analyzed
55 by recording adverse events during the whole course of this trial. This study
56 was registered with Chictr.org (ChiCTR2200066416).

57

58 **Findings** Of 513 enrolled participants, 173 in the A8G6 treatment group and
59 340 in the blank-control group were included in the analysis. SARS-CoV-2
60 infection occurred in 151/340 (44.4%) subjects in the blank control group and
61 12/173 (6.9%) subjects with the A8G6 treatment group. The result indicates
62 that the intranasal spray A8G6 reduces the risk of SARS-CoV-2 infection
63 (HR=0.12, 95% CI, 0.07-0.22; $p<0.001$). The prevention efficacy of the A8G6
64 treatment within 72-hours exposure was calculated to be 84.4% (95% CI:
65 74.4%-90.4%). Moreover, compared to the blank-control group, the time from
66 the SARS-CoV-2 negative to the positive COVID-19 conversion was
67 significantly longer in the AG86 treatment group (mean time: 3.4 days in the
68 A8G6 treatment group vs 2.6 days in the control group, $p=0.019$). In the
69 secondary end-point analysis, the A8G6 nasal treatment had no effects on the
70 viral load at baseline SARS-CoV-2 RT-PCR positivity and the time of the
71 negative COVID-19 conversion (viral clearance). Finally, 5 participants (3.1%)
72 in the treatment group reported general adverse effects. We did not observe
73 any severe adverse effects related to the A8G6 treatment in this study.

74

75 **Interpretation** In this study, the intranasal spray AG86 antibody cocktail
76 showed potent efficacy for prevention of SARS-CoV-2 infection in close
77 contacts of COVID-19 patients.

78

79 **Funding** Chongqing Biomedical R&D Major Special Project, Project (No.
80 CSTB2022TIAD-STX0013), Chongqing Science and Health Joint Medical
81 High-end Talent Project (No. 2022GDRC012), Science and Technology
82 Research Program of Chongqing Municipal Education Commission (No.
83 KJZD-K202100402), CQMU Program for Youth Innovation in Future Medicine
84 (No. W0073).

85 **Research in context**

86 *Evidence before the study*

87 Two potent neutralizing antibodies 55A8 and 58G6 against SARS-CoV-2 were
88 identified from the plasma of COVID-19 convalescent patients. In our previous
89 studies, the synergetic neutralization of the antibody combination of 55A8 and
90 58G6 (A8G6) had been shown in structural mechanism, as well as in vitro and
91 in vivo. Pre-clinical evaluation of A8G6 nasal spray showed promising efficacy
92 against Omicron BA.4/5 infection in golden syrian hamsters challenged with
93 live virus. In a first-in-human trial, A8G6 also showed favorable safety profile
94 and nasal concentration over IC90 of neutralization activity against Omicron
95 BA.4/5. The preliminary data showed that the intranasal spray A8G6 had the
96 excellent efficacy, safety and druggability to protect against COVID-19.

97

98 *Added value of this study*

99 This is the first human trial showing that a nasal spray of neutralizing antibody
100 cocktail is efficacious in preventing SARS-CoV-2 infection but is not efficacious
101 in the post-infection treatment of COVID-19. In the Omicron wave of the
102 COVID-19 pandemic in China in November, 2022, COVID-19 close contacts
103 receiving the A8G6 treatment in the designated quarantine hotels showed a
104 significantly lower incidence of SARS-CoV-2 infection. Additionally, the A8G6
105 treatment delayed time from exposure to the diagnosis of the COVID-19
106 positivity (median time: 3.4 days in the treatment group vs 2.6 days in the

107 control group). Furthermore, we analyzed the effects of the A8G6 treatment on
108 the clinical status of close contacts who became infected with SARS-CoV-2.
109 Results suggests that there were no significant differences in viral load of
110 SARS-CoV-2 at the beginning of positive infection and the time of the viral
111 clearance between A8G6 treatment and blank control groups. Overall, the trial
112 result is consistent with the mechanism of action of nasal spray antibody
113 cocktail for the prevention of SARS-CoV-2 infection. Finally, low safety risk of
114 the nasal spray A8G6 was also shown in the trial.

115

116 *Implications of all the available evidence*

117 We observed the use of A8G6 to reduce the risk of SARS-CoV-2 infection.
118 This study provided supporting evidences for the real-world effectiveness and
119 safety of the nasal spray A8G6 among high-risk close contacts in the
120 post-exposure prevention of COVID-19 during the Omicron BA.5.2 wave in
121 China. This is the first proof of concept of using nasal spray neutralizing
122 antibody for the prevention of viral infection. It implicates that the promising
123 efficacy of the nasal spray A8G6 makes it possible for the fast-acting
124 prevention in future COVID-19 waves.

125 **1. Introduction**

126 At present, SARS-CoV-2 is still defined as a Public Health Emergency of
127 International Concern. Due to the continuous evolution of SARS-CoV-2, its
128 variants led to a high risk of COVID-19 global transmission. Although
129 vaccination played important roles in the preventing and controlling of
130 COVID-19,^{1,2} the neutralizing antibodies (NAbs) elicited by vaccines were
131 heterogeneous among different individuals and were waning within several
132 months.³⁻⁵ NAbs blocking the entry of SARS-CoV-2 into host cells have been
133 developed for the COVID-19 prevention or therapy. Several SARS-CoV-2
134 targeting monoclonal antibodies (mAbs) have previously been authorized for
135 use through an emergency use authorization (EUA).⁶⁻¹⁰ However, due to the
136 failure or significant decrease of neutralization against some emerging
137 SARS-CoV-2 variants, the usage of these antibody drugs was limited. There is
138 an urgent need to develop broad-spectrum and effective NAbs against the
139 circulating and other novel SARS-CoV-2 variants. Furthermore, those
140 approved neutralizing antibodies, when administrated systematically, provided
141 limited efficacy in the prevention of viral infection. We hypothesized that this
142 was due to the low concentration of those neutralizing antibodies at nasal
143 compartment when administered systematically. As a potentially more effective
144 prophylactic approach, we proposed to use neutralizing antibodies as nasal
145 spray to prevent viral infection at the viral entry point to human body.

146

147 A8G6 was a combination of 58G6 and 55A8 monoclonal NAbS which were
148 identified from COVID-19 convalescent patients at early 2020.¹¹ Previous
149 study showed that 58G6 recognized both the steric site S⁴⁷⁰⁻⁴⁹⁵ and another
150 region S⁴⁵⁰⁻⁴⁵⁸ on the receptor binding domain (RBD) of SARS-CoV-2 spike
151 protein (S protein). When administrated as a nasal spray, 58G6 demonstrated
152 prophylactic efficacy against authentic SARS-CoV-2 ancestral strain and the
153 Beta variant (B.1.351) in the transgenic mice expressing human ACE2 (hACE2)
154 and against Delta and Omicron variants in hamster model.^{12,13} 55A8 exhibited
155 potent binding affinities to the S proteins of ancestral SARS-CoV-2 strain,
156 Delta, Omicron BA.1, BA.2, and BA.4/5 at sub-picomolar level. When the two
157 NAbS simultaneously interacted with S protein, 58G6 and 55A8 recognized
158 different and complementary epitopes in RBD of SARS-CoV-2 and further
159 occluded the accessibility of the S protein to ACE2. Therefore, A8G6 antibody
160 cocktail which consisted of two potent neutralizers 58G6 and 55A8 displayed a
161 synergetic potency and the broad neutralization against the Omicron
162 variants.¹⁴ Moreover, intranasal delivery of the cocktail A8G6 demonstrated
163 potent protection against Omicron in hamster model. A first-in-human trial of
164 the intranasal spray A8G6 antibody cocktail in healthy volunteers provided
165 evidences for safety and the potential clinical efficacy in preventing Omicron
166 BA.4/5 infections (unpublished, manuscript in preparation). The real-world
167 effectiveness of the A8G6 nasal spray needs to be further evaluated.

168

169 Here we conducted an open-label, non-randomized, two-arm, blank-controlled
170 trial among close contacts of COVID-19 patients in several designated
171 quarantine hotels to assessed the effectiveness and safety of A8G6 intranasal
172 spray for the post-exposure prophylaxis of COVID-19 during the Omicron
173 BA.5.2 wave occurred in November, 2022 in Chongqing, China.

174

175 **2. Methods**

176 **Study design**

177 In this study, an open-label, non-randomized, two-arm, blank-controlled,
178 investigator-initiated trial was designed to assess the efficacy and safety of the
179 intranasal spray cocktail A8G6 in preventing SARS-CoV-2 infection among
180 close contacts with COVID-19 patients. The clinical trial was conducted at 6
181 designated quarantine hotels in Yuzhong District, Chongqing, China from
182 November 27, 2022 and was completed on December 12, 2023.

183

184 Recruited participants in the treatment group self-administrated a three doses
185 of 0.7 mg (140µl) A8G6 nasal spray per day for 7 treatment days. The drug
186 was supplied by Chongqing Mingdao Haoyue Biotechnology Co., LTD
187 (Chongqing, China), stored at 2-8 °C. In the blank control group, participants
188 did not receive any treatment. After enrollment, SARS-CoV-2 infection was
189 confirmed by a reverse transcription polymerase chain reaction (RT-PCR) test
190 of oropharyngeal swab. During this trial, with the adaption of the

191 anti-COVID-19 policy, not only RT-PCR, but also rapid antigen tests were used
192 to confirm the SARS-CoV-2 infection status.

193

194 The trial was carried out in accordance with all applicable national and local
195 regulatory requirements. Data and Safety Monitoring Board of The Second
196 Affiliated Hospital of Chongqing Medical University oversaw trial conduct and
197 documentation. The protocol has been approved by the Chinese clinical test
198 registration center (the world health organization international clinical trials
199 registered organization registered platform (ICTRP), the registration number:
200 ChiCTR2200066416) and the Ethics Committees of The Second Affiliated
201 Hospital of Chongqing Medical University (the approval number: 2022127-1).

202

203 **Participants**

204 During November COVID-19 wave in Chongqing, China, when patients had
205 been diagnosed as COVID-19 with the positive RT-PCR test for SARS-CoV-2
206 (index cases), their close contacts were immediately transferred to the
207 designated quarantine sites. At 6 quarantine sites in Chongqing, healthy adults
208 aged between 18 to 65 years who had a close contact with index cases within
209 72 hours were enrolled into this study. The maximum time interval between
210 exposure to treatment was ≤ 72 hours. All vaccination status is eligible for
211 inclusion. Exclusion criteria included positive RT-PCR at baseline, nasal
212 discomfort, the use of other COVID-19 antibody drugs and drug-drug

213 interference with participants' regular medication (additional details about
214 eligibility criteria were described in the appendix).

215

216 All study participants were capable of self-administrating the intranasal spray,
217 recording and recalling clinical signs. All participants were provided and
218 voluntarily signed written informed consent before the study.

219

220 **Procedures**

221 At six quarantine sites in the Yuzhong District, Chongqing, site investigation
222 was carried out to screen eligible participants. Eligible participants were given
223 the choice to join the A8G6 treatment group or blank control group. For eligible
224 participants that showed "no preference" in either group, they were randomly
225 assigned to A8G6 treatment group or blank control group. Oropharyngeal
226 swabs were taken for quantitative and qualitative RT-PCR assessments at
227 baseline prior to treatment and though the treatment period and a follow-up
228 period. Subjects with positive RT-PCR results before treatment were excluded.
229 The SARS-CoV-2 viral load was present by viral genome copies per mL log₁₀
230 values with the conversion of the open reading frame of 1ab (ORF1ab) and
231 nucleocapsid (N-gene) cycle threshold (Ct) values (RT-PCR was conducted by
232 Yuzhong District Center for Disease Control and Prevention, in Chongqing,
233 China. Conversion of Ct values to viral genome copies was calculated
234 according to the manufacturer's instructions of 2019-nCoV viral RNA kit

235 produced by BioPerfectus Technologies, catalog number: JC10223-1N).

236

237 Subjects' demographic data, health and COVID-19 vaccination status were
238 recorded at the baseline visit (Day 0). The use of nasal spray, rapid antigen
239 tests or RT-PCR test for COVID-19 were recorded every day during the study
240 participation. When participants in both groups were diagnosed with
241 SARS-CoV-2 infection, the related symptoms and symptomatic treatment for
242 COVID-19 were reported until the trial completed. In the treatment group, all
243 participants were requested to self-report and record the adverse events. Due
244 to the relaxation of COVID-19 control and policy starting from December 4,
245 2022, some participants returned to home for further isolation. The follow-up
246 visits were adjusted to retrospective telephonic visit according to a
247 questionnaire form from that day.

248

249 **Outcomes**

250 The primary endpoint analysis included all participants in both the treatment
251 and control groups. The primary endpoint was to assess the efficacy of the
252 intranasal spray A8G6 for post-exposure prophylaxis of COVID-19. In this
253 study, we compared the COVID-19 incidence of the close contacts between
254 the A8G6 treatment individuals and the blank-controlled individuals. We also
255 compared the time from enrollment to SARS-CoV-2 infection between the two
256 groups. The secondary efficacy analysis included the quantitative data of

257 SARS-CoV-2 RNA (log₁₀ copies per mL) at baseline of the positive COVID-19,
258 the time to conversion of SARS-CoV-2 RNA from positive to negative (viral
259 clearance) and the time to symptom remission of COVID-19 patients.

260

261 Safety endpoints was adverse event types and the incidence rate of adverse
262 events among all participants of the A8G6 treatment group during the study.

263 An adverse effect was defined as any abnormal signs or symptoms and
264 harmful results caused by the study drug.

265

266 **Statistical analysis**

267 The sample size in this clinical trial was determined on the basis of statistical
268 power calculations. We proposed greater than 90% power to detect a 20%
269 relative difference between the A8G6 treated and control group at a two-sided
270 alpha level of 0.05 (ie., a 20% prevention efficacy of A8G6). The formula is as
271 follows:

$$n = \frac{2pq(Z_{1-\frac{\alpha}{2}} + Z_{1-\beta})^2}{\delta^2}$$

272 which p is the proportion of participants develop COVID-19 in A8G6 treated
273 group, q is in the control group, δ is the difference between two group, α is
274 two-sided alpha level, and $1-\beta$ is statistical power. In this clinical trial, we
275 assume that q is 0.1, 20% relative reduction of A8G6 treated group is 0.08.

276 Assuming a dropout rate of 20%, at total of 5160 participants will be recruited.

277

278 The primary efficacy endpoints including COVID-19 incidence and time to
279 confirmed SARS-CoV-2 infection. The COVID-19 incidence was analyzed
280 using the Kaplan-Meier method and log-rank test, and the time to confirmed
281 SARS-CoV-2 infection was analyzed using Wilcoxon rank-sum test. The
282 secondary efficacy endpoints including viral load when confirmed
283 SARS-CoV-2 infection and the time to negative conversion of SARS-CoV-2
284 determined by RT-PCR. The viral load when confirmed SARS-CoV-2 infection
285 was analyzed using Wilcoxon rank-sum test, negative conversion of
286 SARS-CoV-2 and remission time were conducted using Kaplan-Meier method
287 and log-rank-test. Safety was assessed in participants in the full analysis set
288 who received A8G6 nasal spray treatment during the 8-day quarantine period.

289

290 Database from the Service Platform for COVID-19 Prevention and Control
291 created by Yuzhong District Center for Disease Control and Prevention were
292 authorized for us to use and analyze. Data including demographic and clinical
293 characteristics of the cohorts, endpoints in this clinical trial were collected from
294 an applet of WeChat (a social media platform in China), called “Yuzhong
295 Information Exchange”. All data were summarized with descriptive statistics
296 (number of subjects (%), median (IQR), mean±sd). The credible interval for
297 nasal spray was calculated with the use of a beta-binomial model with prior
298 beta (1, 1) adjusted for the treatment duration time. Continuous variables were

299 compared with the Mann–Whitney U-test, and Categorical variables were
300 conducted using χ^2 test or Fisher's exact test. A P value of <0.05 was
301 considered statistically significant. Statistical analyses were performed using R
302 software, version 3.6.0.

303

304 **Role of the funding source**

305 The funder of the study had no role in study design, data collection, data
306 analysis, data interpretation, or writing of the report. All authors
307 had full access to all the data in the study and had final responsibility for the
308 decision to submit for publication.

309

310 **3. Results**

311 Since November 27, 2022, a total of 657 individuals were screened in the
312 designated quarantine hotels. There were 101 individuals excluded according
313 to the inclusion and exclusion criteria. The remaining 556 individuals were
314 assigned into either A8G6 treatment group or blank-controlled group based on
315 their preference during signing of consent form. For participants who indicated
316 “no preference” in study group assignment, they were randomly assigned to
317 A8G6 treatment group or the blank control group. Ten participants in the
318 treatment group and 33 participants in the control group were excluded due to
319 consent withdrawal or loss to follow up (Figure 1). The full analysis set (n=513)
320 included all participants who received the A8G6 treatment or blank-control and

321 completed the study. The per-protocol population (n=162) in the treatment
322 group comprised participants who received the A8G6 treatment or no
323 treatment, were treated within 72 hours after exposure.

324

325 The final number of subjects completing the trial was 173 subjects in the A8G6
326 treatment group and 340 subjects in the control group, respectively. In the
327 treatment group, 4 participants started to self-administrated A8G6 at the same
328 day after exposure (Day 0); 73 participants used the nasal spray at the first day
329 after exposure (Day 1); 49 participants at the second days after exposure (Day
330 3); 35 participants at the third day after exposure (Day 3) and 12 participants at
331 more than 4 days after exposure (Day \geq 4). Among all participants in the full
332 analysis set, median age was 36.0 (interquartile range, IQR: 26.0-48.0) years;
333 there was a comparable sex ratio between the A8G6 group (55.5% for male
334 and 44.5% for female) and the control group (58.2% for male and 41.8% for
335 female); median BMI was 22.9 (IQR: 20.8-25.4); 18 (10.4%) participants in the
336 treatment group have comorbidities, while 44 (12.9%) participants in the
337 control group have comorbidities. 98.6% participants received different doses
338 of COVID-19 vaccines (Table 1).

339

340 **Efficacy of A8G6 nasal spray in the post-exposure prevention of** 341 **SARS-CoV-2 infection**

342 After enrollment, oropharyngeal swabs of all subjects in the full analysis set

343 were taken for RT-PCR test for SARS-CoV-2 infection every day. In total,
344 163/513 (31.8%) participants developed COVID-19 during the 14-day
345 follow-up study. Among them, 12/173 (6.9%) individuals were in the A8G6
346 treatment group and 151/340 (44.4%) were in the blank control group (Table
347 1-3, Figure 2A). This difference in COVID-19 incidence rate between groups
348 was statistically significant (Hazard ratio, HR=0.12, 95% CI, 0.07-0.22;
349 log-rank $p<0.001$). The mean (\pm SD) time of the positive COVID-19 conversion
350 was significantly longer in the A8G6 group compared to the control group
351 (3.4 ± 1.1 days vs 2.6 ± 1.2 days, $p=0.019$) (Figure 2B). Similar results of data
352 analysis were obtained in the per protocol set (data not shown).

353

354 **The effect of A8G6 on the viral load of SARS-CoV-2 infection at baseline**

355 After enrollment, oropharyngeal swabs of all subjects were taken for RT-PCR
356 test for SARS-CoV-2 every day. When participants were diagnosed as
357 SARS-CoV-2 infection, the Ct values of ORF1ab and N genes were recorded
358 and converted into copies per mL log₁₀ values. Five subjects (41.7%) in the
359 A8G6 treatment group had high viral load ($>10^5$ copies/ml) of the ORF1ab
360 gene, compared with 69 subjects (45.7%) in the control group (Table 3); Five
361 subjects (41.7%) in the A8G6 treatment group had high viral load of the N gene
362 ($>10^5$ copies/ml), compared with 100 subjects (66.2%) in the control group.
363 There were no significant differences on the percentage of participants with
364 high viral load of these two genes ($p=1.000$ and 0.117 , respectively) between

365 the two groups. That is, despite participants received the A8G6 treatment,
366 when they became infected with SARS-CoV-2, they had a comparable level of
367 viral load compared to infected participants in the blank control group (Figure
368 3). The same analysis conducted in the per protocol set obtained the
369 consistent results.

370

371 **The effect of A8G6 on the time to the COVID-19 recovery**

372 When participants became infected with SARS-CoV-2 in both groups, RT-PCR
373 tests or rapid antigen tests of their oropharyngeal swabs for COVID-19 and the
374 COVID-19 related symptoms were continuously monitored and recorded.
375 Subjects in both groups who were infected with SARS-CoV-2 during the trial
376 period reported the conversion to COVID-19 negative by the end of the trial.
377 The time of SARS-CoV-2 negativity between groups showed no statistical
378 differences ($p=0.946$) (Figure 4). There is a similar result in the per protocol
379 set.

380

381 **Safety**

382 Participants receiving A8G6 treatment (n=173) were required to recorded
383 adverse events (AEs). Thereinto, AEs reported by COVID-19 negative
384 participants (n=161) were not correlated with COVID-19, but might be
385 correlated with the A8G6 treatment. AEs reported by COVID-19 positive
386 participants (n=12) might be correlated with COVID-19 or A8G6. Therefore,

387 after the exclusion of AEs related to COVID-19, the presumptive AEs related to
388 A8G6 treatment were analyzed. Total of 96.9% of the participants in the A8G6
389 treatment group had no treatment-related adverse effects. Only 3.1% subjects
390 reported one adverse event. The special performance included nasal swelling
391 (N=2, 1.24%), dry throat (N=2, 1.24%) and ageusia (N=1, 0.62%) (Table 4). No
392 adverse events of special interest were reported during the trial period, and no
393 participants withdrew from the trial because of an adverse event. There is a
394 similar result in the per protocol set.

395

396

397

398

399 **4. Discussion**

400 The nasal spray antibody cocktail A8G6 had demonstrated broad spectrum
401 potency blocking the SARS-CoV-2 infection in our previous preclinical data
402 and also demonstrated favorable safety profile in a first-in-human trial
403 (unpublished data, manuscript in preparation). In this study, we conducted an
404 open-label, non-randomized, two-arm, blank-controlled trial among close
405 contacts of COVID-19 patients in several designated quarantine hotels, during
406 the COVID-19 outbreak occurred in November, 2022 in Chongqing, China.
407 The intranasal spray antibody cocktail A8G6 was assessed to the
408 effectiveness and safety for the post-exposure prophylaxis of COVID-19 in the
409 real-world. Our data suggest that the application of A8G6 in the close contacts
410 within the 72-hour exposure decreased COVID-19 incidence rate by more than
411 30%. Moreover, the A8G6 treatment prolonged the occurrence of SARS-CoV-2
412 infection by at least one day.

413

414 At present, most previously authorized COVID-19 antibody treatments under
415 EUA were administrated via vein or intramuscular injection with a high dosage.
416 Those treatment also had several adverse effected that affect quality of life,
417 including pain at the site of injection, allergic reaction, nausea and so on.¹⁵ As
418 a respiratory pathogen, SARS-CoV-2 infection is primarily caused by breathing
419 in infectious viral particles through nasal airway. An intranasal spray of
420 neutralizing antibodies may provide a more direct protection against viral entry.

421 Moreover, this non-invasive drug delivery is easier to use and may result in
422 better medication compliance. In our study, the favorable safety profile of
423 A8G6 with the few adverse effects was consistent with other nasal spray
424 drugs.¹⁶ Thus, A8G6 can be used in a wide range of population, especially in
425 some special population with comorbidities and immunocompromised
426 population. The effective treatment of A8G6 among high-risk patients could
427 reduce medical cost, usage of medical resources and COVID-19 transmission
428 risk. Furthermore, participants who experienced SARS-CoV-2 infection under
429 the A8G6 treatment, showed delayed COVID-19 infection by ~ 1 day, which
430 could provide important relieve on medical resources at the epidemic peak.

431

432 Currently, there were a few other antibody nasal sprays in clinical development.
433 The neutralization efficacy of nasal mucosal samples against SARS-CoV-2
434 variants after the nasal spray treatment of a monoclonal antibody 35B5 was
435 calculated as 60%.¹⁷ The effectiveness of the SA58 nasal spray was evaluated
436 as 77.7% (95% CI: 52.2% - 89.6%) and 61.83% (95% CI: 37.5% - 76.69%) in
437 medical personnel and healthy workers, respectively.^{18,19} In our primary
438 endpoint analysis, the nasal spray A8G6 antibody cocktail showed decreased
439 risk of infection of close contacts with COVID-19 patients. The prevention
440 efficacy of the A8G6 treatment within 72-hour exposure was calculated to be
441 84.4% (95% CI: 74.4-90.4). A8G6 showed comparable or better COVID-19
442 prevention in the real world than other similar antibody nasal spray.

443

444 Current data in this study showed that 6.9% of A8G6 treated participant
445 became SARS-CoV-2 positive (vs 44.4% in the blank control group) during the
446 study period. Our results suggested that post-infection A8G6 treatment
447 provided limited benefits on viral load reduction and time to viral clearance.
448 This is consistent with the potential mechanism of action of A8G6 nasal spray.
449 Once SARS-CoV-2 virus enters into the cells and starts viral replication, A8G6
450 neutralizing antibody has limited efficacy to stop the viral replication. Our data
451 also indicated that baseline characteristics of these two groups in the efficiency
452 of viral replication were similar.²⁰ In another study, the similar viral load were
453 also reported between the vaccinated individuals with breakthrough infections
454 and unvaccinated individuals with SARS-CoV-2 infection.²¹

455

456 There were several limitations for this study. First limitation is the lack of a
457 placebo arm. We did not conduct this study with the double-blind procedure
458 because there was a small window of time to initiate and complete the study so
459 not allowing enough time for the placebo to be produced before the trial.
460 Second limitation is the lack of participant randomization in the study design.
461 This was primarily due to a large percentage of eligible participants not feel
462 comfortable to take the A8G6 treatment at time of enrollment. Therefore, we
463 have to assign those participants to blank-controlled group. Under this
464 situation, complete randomization was not possible. Third limitation is the lack

465 of participants developing severe COVID-19 that need hospitalization due to
466 small sample size. Therefore, this study did not assess the efficacy of A8G6 in
467 preventing severe COVID-19. During the study period, there was an
468 adjustment of the public health policy of the COVID-19 pandemic in China, that
469 the SARS-CoV-2 infected persons no longer were reported in the future. As a
470 result, the definition of close contacts became difficult and it became difficult to
471 enroll more participants to increase the sample size. Fourth limitation is that
472 the study was conducted in the designated quarantine hotels. Study
473 participants were assumed to be single-exposure to positive COVID-19
474 individuals. The effects of increased infection risks of multiple exposures in the
475 real world on the A8G6 efficacy should be considered in the further study.

476

477 In conclusion, we observed potent post-exposure prevention efficacy of
478 intranasal spray AG86 antibody combination in close contacts of COVID-19
479 patients. This proof-of-concept study result suggested the potential beneficial
480 effect of neutralizing antibody administrated as nasal spray in COVID-19
481 prevention. Currently A8G6 nasal spray is under clinical development to further
482 assess its efficacy and safety.

483

484 **Contributors**

485 AH, NT and XL designed the trial and study protocol. PP contributed to the
486 literature search. XL and HD verified the data. PP and HD wrote the first draft
487 manuscript. AH, NT, XL, PP, HD and ZY contributed to the data interpretation
488 and revision of the manuscript. HD, XL, NT and PP contributed to data
489 analysis. XL monitored the trial. QY, SC, BL, MH and XL were responsible for
490 the site work including the recruitment, follow-up, and data collection, and XL
491 was the site coordinator. All the authors had full access to all the data in the
492 study and had final responsibility for the decision to submit for publication.

493

494 **Declaration of interests**

495 All authors declare no competing interests.

496

497 **Data sharing**

498 De-identified individual participant-level data will be available upon written
499 request to the corresponding author following publication.

500

501 **Acknowledgements**

502 We thank Dr. Yang Tian and Chengyong Yang (Mindao Haoyue Co., Ltd.
503 , Chongqing, China) for the constructive suggestion about the trial design and
504 manuscript. We thank all the participants who took part and contribute
505 specimens in our study. We also thank the support from Yuzhong District
506 Center for Disease Control and Prevention (Chongqing) and all medical

507 personnels who worked hard in this trial.

508

509 **Figures and Tables**

510 **Table 1. Demographic and Clinical Characteristics of the Cohort.**

| Characteristic | A8G6 (N=173) | Control (N=340) | Total (N=513) |
|-----------------------------------|------------------|------------------|------------------|
| Age | | | |
| Median age (IQR, year) | 29.0 (24.0-40.0) | 41.0 (30.0-50.0) | 36.0 (26.0-48.0) |
| Mean±sd | 32.6±10.4 | 40.1±12.2 | 37.6±12.2 |
| Sex | | | |
| Male | 96 (55.5%) | 198 (58.2%) | 294 (57.3%) |
| Female | 77 (44.5%) | 142 (41.8%) | 219 (42.7%) |
| Weight (mean±sd) | | | |
| | 60.0 (53.0-70.0) | 63.0 (55.0-70.0) | 63.0 (55.0-70.0) |
| BMI (mean±sd) | | | |
| | 22.2 (19.6-24.5) | 23.1 (21.3-25.6) | 22.9 (20.8-25.4) |
| Comorbidities | | | |
| Metabolic disease | 6 (3.5%) | 28 (8.2%) | 34 (6.6%) |
| Respiratory disease | 3 (1.7%) | 7 (2.1%) | 10 (1.9%) |
| Cardiovascular diseases | 1 (0.6%) | 1 (0.3%) | 2 (0.4%) |
| Other | 8 (4.6%) | 8 (2.4%) | 16 (3.1%) |
| All | 18 (10.4%) | 44 (12.9%) | 62 (12.1%) |
| Vaccine type | | | |
| Inactivated vaccine | 156 (90.2%) | 317 (93.2%) | 473 (92.2%) |
| Recombinant vaccine | 12 (6.9%) | 17 (5.0%) | 29 (5.7%) |
| Inactivated + Recombinant vaccine | 3 (1.7%) | 1 (0.3%) | 4 (0.8%) |
| Unvaccinated | 2 (1.2%) | 5 (1.5%) | 7 (1.4%) |

Dose

| | | | |
|---------|-------------|-------------|-------------|
| 0-dose | 2 (1.2%) | 5 (1.5%) | 7 (1.4%) |
| 1-dose | 0 (0.0%) | 5 (1.5%) | 5 (1.0%) |
| 2-dose | 30 (17.3%) | 42 (12.4%) | 72 (14.0%) |
| 3-dose | 140 (80.9%) | 286 (84.1%) | 426 (83.0%) |
| 4-dose | 1 (0.6%) | 1 (0.3%) | 2 (0.4%) |
| Missing | 0 (0.0%) | 1 (0.3%) | 1 (0.2%) |

COVID-19 outcome

| | | | |
|-----------------|-------------|-------------|-------------|
| Positive (n, %) | 12 (6.9%) | 151 (44.4%) | 163 (31.8%) |
| Negative (n, %) | 161 (93.1%) | 189 (55.6%) | 350 (68.2%) |

511

512

513

514

515

516

517 **Table 2. Demographic and Clinical Characteristics of COVID-19 positive**
 518 **individuals**
 519

| Characteristic | A8G6 (N=12) | Control (N=151) | P value |
|---|------------------|------------------|---------|
| Age | | | 0.103 |
| Median age (IQR, year) | 36.0 (31.2-45.5) | 42.0 (32.0-51.0) | |
| Mean±sd | 36.3±10.4 | 41.8±12.0 | |
| Sex | | | 0.375 |
| Male | 8 (66.7%) | 77 (51.0%) | |
| Female | 4 (33.3%) | 74 (49.0%) | |
| Weight (mean±sd) | 61.5 (58.8-66.2) | 63.0 (55.0-70.0) | 0.934 |
| BMI (mean±sd) | 21.4 (20.9-23.2) | 23.7 (21.4-26.0) | 0.057 |
| Clinical phenotype | | | 0.694 |
| Symptomatic | 11 (91.7%) | 127 (84.1%) | |
| Asymptomatic | 1 (8.3%) | 24 (15.9%) | |
| Days to COVID-19 confirmed | | | 0.019 |
| median days, IQR | 3.5 (2.8-4.0) | 3.0 (2.0-3.0) | |
| Mean±sd | 3.4±1.1 | 2.6±1.2 | |
| Duration of SARS-CoV-2 positive (day) | | | 0.724 |
| median days, IQR | 6.5 (5.0-7.2) | 7.0 (4.0-7.0) | |
| Mean±sd | 6.7±1.9 | 6.3±2.5 | |
| Viral load (Conversion according to Ct value of ORF1ab gene) | | | 1.000 |

| | | | |
|--|---------------|---------------|-------|
| High level, >10 ⁵ copies/ml | 5 (41.7%) | 69 (45.7%) | |
| Low level, <10 ⁵ copies/ml | 7 (58.3%) | 82 (54.3%) | |
| Viral load (Conversion according to Ct value of N gene) | | | 0.117 |
| High level, >10 ⁵ copies/ml | 5 (41.7%) | 100 (66.2%) | |
| Low level, <10 ⁵ copies/ml | 7 (58.3%) | 51 (33.8%) | |
| Symptomatic treatment | | | 0.039 |
| Western medicine | 11 (91.7%) | 89 (58.9%) | |
| Traditional chinese medicine | 0 (0.0%) | 8 (5.3%) | |
| Combination of western and traditional chinese medicine | 1 (8.3%) | 6 (4.0%) | |
| Untreated | 0 (0.0%) | 48 (31.8%) | |
| Duration of Covid-19 symptoms (d) | | | 0.401 |
| median days, IQR | 5.0 (1.5-5.0) | 3.0 (2.0-4.5) | |
| Mean±sd | 4.3±2.9 | 4.2±5.0 | |
| Comorbidities | | | 0.435 |
| Metabolic disease | 1 (8.3%) | 17 (11.3%) | |
| Respiratory disease | 1 (8.3%) | 2 (1.3%) | |
| Cardiovascular diseases | 0 (0.0%) | 1 (0.7%) | |
| Other | 1 (8.3%) | 5 (3.3%) | |
| All | 3 (25.0%) | 25 (16.6%) | |
| Vaccine type | | | 0.203 |
| Inactivated vaccine | 10 (83.3%) | 143 (94.7%) | |

| | | | |
|---------------------------|------------|-------------|-------|
| Recombinant vaccine | 2 (16.7%) | 5 (3.3%) | |
| Unvaccinated | 0 (0.0%) | 3 (2.0%) | |
| Dose | | | 1.000 |
| 0-dose | 0 (0.0%) | 3 (2.0%) | |
| 1-dose | 0 (0.0%) | 1 (0.7%) | |
| 2-dose | 2 (16.7%) | 24 (15.9%) | |
| 3-dose | 10 (83.3%) | 123 (81.5%) | |
| Signs and symptoms | | | |
| Fever | 10 (83.3%) | 83 (55.0%) | 0.071 |
| Fatigue | 4 (33.3%) | 22 (14.6%) | 0.102 |
| Dry cough | 6 (50.0%) | 54 (35.8%) | 0.361 |
| Headache | 3 (25.0%) | 39 (25.8%) | 1.000 |
| Dizziness | 0 (0.0%) | 5 (3.3%) | 1.000 |
| Ageusia | 2 (16.7%) | 8 (5.3%) | 0.161 |
| Pharyngalgia | 1 (8.3%) | 12 (7.9%) | 1.000 |
| Myalgia | 2 (16.7%) | 37 (24.5%) | 0.733 |
| Chill | 1 (8.3%) | 3 (2.0%) | 0.266 |
| Rhinorrhea | 0 (0.0%) | 2 (1.3%) | 1.000 |
| Nasal congestion | 0 (0.0%) | 2 (1.3%) | 1.000 |
| Diarrhea | 0 (0.0%) | 4 (2.6%) | 1.000 |
| Anorexia | 1 (8.3%) | 6 (4.0%) | 0.421 |
| Vomiting | 1 (8.3%) | 1 (0.7%) | 0.142 |

| | | | |
|----------------|------------|-------------|-------|
| Arthralgia | 2 (16.7%) | 4 (2.6%) | 0.063 |
| Nausea | 0 (0.0%) | 2 (1.3%) | 1.000 |
| Abdominal pain | 0 (0.0%) | 1 (0.7%) | 1.000 |
| Dry throat | 0 (0.0%) | 2 (1.3%) | 1.000 |
| Insomnia | 0 (0.0%) | 2 (1.3%) | 1.000 |
| Somnolence | 0 (0.0%) | 2 (1.3%) | 1.000 |
| Asthma | 0 (0.0%) | 1 (0.7%) | 1.000 |
| Expectoration | 1 (8.3%) | 0 (0.0%) | 0.074 |
| Eye swelling | 1 (8.3%) | 0 (0.0%) | 0.074 |
| Any | 11 (91.7%) | 127 (84.1%) | 0.694 |

520

521

522

523

524

525

526

527

528

529 **Table 3. Primary and Key Secondary Efficacy End Points.**

| End Points | A8G6 (n=178) | Control (n=340) |
|--|------------------|-----------------|
| Primary end point | | |
| SARS-CoV-2 confirmed by RT-qPCR | | |
| No. of participants (%) | 12 (7.0%) | 151 (44.4%) |
| Hazard ratio (95% CI) | 0.12 (0.07-0.22) | - |
| log rank P value | 3.95E-21 | - |
| Days to SARS-CoV-2 confirmed | | |
| Total No. of days | 41 | 392 |
| Mean days to SARS-CoV-2 confirmed (days) | 3.4 | 2.6 |
| P value | 0.019 | - |
| Key secondary end points | | |
| High viral load at SARS-CoV-2 confirmed, ORF1ab >10 ⁵ copies/ml | | |
| No. of participants (%) | 5 (41.7%) | 69 (45.7%) |
| P value | 1.000 | - |
| High viral load at SARS-CoV-2 confirmed, N >10 ⁵ copies/ml | | |
| No. of participants (%) | 5 (41.7%) | 100 (66.2%) |
| P value | 0.117 | - |
| SARS-CoV-2 negative conversion | | |
| No. of participants (%) | 12 (100.0%) | 151 (100.0%) |
| Hazard ratio (95% CI) | 0.98 (0.54-1.77) | - |
| log rank P value | 0.946 | - |

Duration of SARS-CoV-2 positive (day)

| | | |
|---|-------|-----|
| Total No. of days | 80 | 917 |
| Mean days of SARS-CoV-2 positive duration | 6.7 | 6.3 |
| P value | 0.724 | - |

530

531

532

533

534

535

536

537

538 **Table 4. Individuals (n) having an adverse event (n=161).**

539


540

541

542


543

| Adverse events | n (%) |
|-----------------------|--------------|
| Nasal swelling | 2 (1.24%) |
| Dry throat | 2 (1.24%) |
| Ageusia | 1 (0.62%) |



544 **Figure 1. Screening and follow-up of participants.**

545




546

547 **Figure 2. Kaplan Meier plot of occurrence of RT-PCR-confirmed**
 548 **COVID-19.**


549

550



551 **Figure 3. SARS-CoV-2 viral load (log₁₀ copies per ml) at baseline when**
552 **diagnosed with COVID-19.**

553



554

555 **Figure 4. Time-to-event curve for time to viral clearance of SARS-CoV-2.**

556

557 **References**

- 558 1. Sharif N, Alzahrani KJ, Ahmed SN, Dey SKJFii. Efficacy, immunogenicity and safety of
559 COVID-19 vaccines: a systematic review and meta-analysis. 2021; 4149.
- 560 2. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BFJNri. Progress of the COVID-19
561 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. 2021;
562 21(10): 626-36.
- 563 3. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the
564 Omicron (B. 1.1. 529) variant. 2022; **386**(16): 1532-46.
- 565 4. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines
566 against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and
567 meta-regression. 2022.
- 568 5. Thomas SJ, Moreira Jr ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA
569 Covid-19 vaccine through 6 months. 2021; **385**(19): 1761-73.
- 570 6. Abramowicz M, Zucotti G, Pflomm MJJ. Tixagevimab and cilgavimab (Evusheld) for
571 pre-exposure prophylaxis of COVID-19. 2022; **327**(4): 384-5.
- 572 7. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in
573 combination with etesevimab on viral load in patients with mild to moderate COVID-19: a
574 randomized clinical trial. 2021; **325**(7): 632-44.
- 575 8. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on hospitalization or
576 death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial.
577 2022; **327**(13): 1236-46.
- 578 9. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron

- 579 sublineages. 2022; **604**(7906): 553-6.
- 580 10. Orders MJMLDT. Casirivimab and imdevimab (REGEN-COV) for post-exposure
581 prophylaxis of COVID-19. 2021; **63**(1631): 130-1.
- 582 11. Han X, Wang Y, Li S, et al. A rapid and efficient screening system for neutralizing
583 antibodies and its application for SARS-CoV-2. 2021; **12**: 653189.
- 584 12. Li T, Han X, Gu C, et al. Potent SARS-CoV-2 neutralizing antibodies with protective
585 efficacy against newly emerged mutational variants. 2021; **12**(1): 6304.
- 586 13. Zhang X, Zhang H, Li T, et al. A potent neutralizing antibody provides protection against
587 SARS-CoV-2 Omicron and Delta variants via nasal delivery. 2022; **7**(1): 301.
- 588 14. Zhang X, Luo F, Zhang H, et al. A cocktail containing two synergetic antibodies broadly
589 neutralizes SARS-CoV-2 and its variants including Omicron BA. 1 and BA. 2. 2022: 2022.04.
590 26.489529.
- 591 15. Abdul A, Slenker AK. Monoclonal antibody therapy for high-risk coronavirus (COVID 19)
592 patients with mild to moderate disease presentations.[Updated 2021 Apr 20]. 2021.
- 593 16. Tandon M, Wu W, Moore K, et al. SARS-CoV-2 accelerated clearance using a novel nitric
594 oxide nasal spray (NONS) treatment: a randomized trial. 2022; **3**.
- 595 17. Lin Y, Yue S, Yang Y, et al. Nasal Spray of Neutralizing Monoclonal Antibody 35B5
596 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2
597 Variants of Concern: A Small-Scale Clinical Trial. 2022.
- 598 18. Si S, Jin C, Li J, et al. Safety and Effectiveness of SA58 Nasal Spray against COVID-19
599 Infection in Medical Personnel: An Open-label, Blank-controlled Study. 2022: 2022.12.
600 27.22283698.

- 601 19. Song R, Zeng G, Yu J, et al. Post-Exposure Prophylaxis with SA58 (anti-COVID-19
602 monoclonal antibody) Nasal Spray for the prevention of symptomatic Coronavirus Disease
603 2019 in healthy adult workers: A randomized, single-blind, placebo-controlled clinical study.
604 2023: 2022.12. 28.22283666.
- 605 20. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel VJNRM. Coronavirus biology and
606 replication: implications for SARS-CoV-2. 2021; **19**(3): 155-70.
- 607 21. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load
608 kinetics of the SARS-CoV-2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated
609 individuals in the UK: a prospective, longitudinal, cohort study. 2022; **22**(2): 183-95.
610